Stock Taper 
TAK
$18.03
▲ UP 0.00% (0.00)
KEY STATISTICS
Market Cap$57.37 B
52w High$18.90
52w Low$12.99
Dividend Yield3.35%
FrequencySemi-Annual
P/E12.96
Volume1.80M
Shares Out.3.18B
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Julie So-Young Kim
ABOUT
SECTOR
Healthcare
WENT PUBLIC
January 5, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
47,029
UPCOMING EARNINGS
DateOct 29, 2026
DayThursday
Rev. Est.$7.23B
OCT
29
THU
PRICE
$18.03 ▲ UP 0.00% (+$0.00)About Takeda Pharmaceutical Company Limited
https://www.takeda.com ↗Takeda is a Tokyo-based global pharma company specializing in gastroenterology, rare diseases, oncology, neuroscience, and plasma therapies, with extensive R&D, licensing, and collaborations worldwide since 1781.
INDUSTRY
Drug Manufacturers - Specialty & Generic
A PRODUCT TAKEDA PHARMACEUTICAL COMPANY LIMITED IS KNOWN FOR
Entyvio (vedolizumab)
Takeda's leading biologic medication treats moderate to severe ulcerative colitis and Crohn's disease, with growing sales and recent FDA approval for a subcutaneous form, reinforcing its status as Takeda's flagship product.
Revenue by Products
| Icon | PRODUCT | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
 | Gastroenterology | $1.09T | $1.22T ▲ | $1.36T ▲ | $1.41T ▲ |
 | PDT Immunology | $678.44B | $818.57B ▲ | $1.03T ▲ | $1.06T ▲ |
 | Rare Diseases | $723.44B | $770.7B ▲ | $752.82B ▼ | $762.7B ▲ |
 | Oncology | $438.74B | $462.36B ▲ | $560.43B ▲ | $580.13B ▲ |
 | Neuroscience | $637.71B | $627.01B ▼ | $565.82B ▼ | $414.34B ▼ |
 | Rare Hematology | $304.72B | $305.3B ▲ | — | — |
 | Other Product | $454.6B | $368.91B ▼ | $257.39B ▼ | $223.96B ▼ |
 | Vaccines | — | — | $55.41B | $59.61B ▲ |
Revenue by Geography
| Map | REGION | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
 | UNITED STATES | $2.1T | $2.2T ▲ | $2.38T ▲ | $2.16T ▼ |
 | Europe And Canada | $842.67B | $966.84B ▲ | $1.06T ▲ | $1.15T ▲ |
 | JAPAN | $512.04B | $451.39B ▼ | $418.46B ▼ | $433.11B ▲ |
 | Asia Excluding Japan | $225.01B | $261.22B ▲ | — | — |
 | Latin America | $160.38B | $198.1B ▲ | $235.85B ▲ | $254.13B ▲ |
 | CHINA | — | — | $191.74B | $195.14B ▲ |
 | Other Countries Not Separately Reported | $95.18B | $117.91B ▲ | $128.85B ▲ | $133.89B ▲ |
 | Asia Excluding Japan And China | — | — | $99.39B | $98.67B ▼ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
21
LISTED HERE
14
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
2.63%
HOLDERS
560
TOP 12 OF 560 · RANKED BY POSITION SIZE
Capital Research Global Investors
Fmr LLC
Morgan Stanley
Tiaa Cref Investment Management LLC
Adage Capital Partners Gp, L.L.C.
Ubs Group AG
Arrowstreet Capital, Limited Partnership
Goldman Sachs Group Inc
Brandes Investment Partners, LP
D. E. Shaw & Co., Inc.
Parametric Portfolio Associates LLC
Renaissance Technologies LLC
RATINGS SNAPSHOT
Overall rating: B
Discounted Cash Flow4
Return On Equity3
Return On Assets3
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score3
TRADES BY CONGRESS
HOUSE TRADES
Virginia Foxx
Sale
2023-08-29
Daniel Goldman
Sale
2023-07-10
Ro Khanna
Purchase
2023-03-10
INSIDER TRADES
★
DIRECTOR, OFFICER: PRESIDENT, R&D
Plump Andrew Stewart
Sale · 19.7K shares
2026-08-19
★
OFFICER: CHIEF HUMAN RESOURCES OFFICER
Greenway Nicola Deidre Petal
Sale · 13.0K shares
2026-08-18
★
OFFICER: PRES., GLOBAL SUPPLY & QUALITY
Shannon Elaine Mary
Sale · 4.0K shares
2026-08-10
★
OFFICER: CHIEF HUMAN RESOURCES OFFICER
Greenway Nicola Deidre Petal
Sale · 33.6K shares
2026-08-10
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 CAH | $234.55 | COMPARE |
 BDX | $189.52 | COMPARE |
 EW | $90.21 | COMPARE |
 VEEV | $276.69 | COMPARE |
 HLN | $10.11 | COMPARE |
 A | $153.85 | COMPARE |
 IQV | $261.75 | COMPARE |
 ALC | $72.01 | COMPARE |